Data presented at the 2010 Conference on Retroviruses & Opportunistic Infections (CROI) showcase new directions in management of HIV disease, including emerging therapies that show promise as potent, safe, convenient and may minimize long-term toxicities.
HIV EXPERTS AVAILABLE FOR INTERVIEW
The following experts are available to provide insights and perspective on the evolving landscape of HIV treatments, the relevance of CCR5s and potential unique properties of TBR-652, based on preliminary data presented at CROI.
/PRNewswire -- Feb. 17/
-- Calvin Cohen, MD, M.Sc., Director of Research, Community Research Initiative of New England -- Kathleen Squires, MD, Professor of Medicine, Jefferson Medical College -- Gerd Fatkenheuer, MD, Head of Infectious Disease, University of Cologne -- Alan Landay, PhD, Director, Developmental Center for AIDS Research -- Jerome Ernst, MD, Medical Director, AIDS Community Research Initiative of America
SOURCE Tobira Therapeutics, Inc.